Clinigen has delivered a solid H1 trading update, underpinning our forecasts for fiscal years 2021 and 2022. As per our detailed November report, we continue to think the business is materially mispriced, with the stock currently trading on 10.9x FY 2021 PE, falling to 8.8x PE for FY 2022. As growth reaccelerates through fiscal year 2022 and with Proleukin newsflow catalysts through 2021, this sets the stage for a material re-rating. We reiterate our ‘Outperform’ rating and £10 price target.
Davy research
Davy ResearchAmryt Pharma - Fiscal year 2020 better across the board
Davy ResearchLufthansa - Restructuring and deleveraging will be a long and painful process
Davy ResearchVistry Group - Company makes very strong start to 2021
Davy ResearchMarket comment - Ireland’s unemployment rate steady at 5.8%
Davy ResearchEntain - Enters 2021 with good US momentum
Davy ResearchOrigin Enterprises - Controlling the controllables; cash flow the stand-out
Davy ResearchCairn Homes - FY results in line with guidance; no material changes likely to forecasts